{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:05:04Z","timestamp":1784891104447,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bioprojet Pharma","award":["Study funding"],"award-info":[{"award-number":["Study funding"]}]},{"name":"Harmony Biosciences, LLC","award":["Funding for analysis; technical editorial and medical writing assistance"],"award-info":[{"award-number":["Funding for analysis; technical editorial and medical writing assistance"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40263-021-00886-x","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T19:51:44Z","timestamp":1640116304000},"page":"61-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials"],"prefix":"10.1007","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01067222","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01800045","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gerard J.","family":"Meskill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Zarycranski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markiyan","family":"Doliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Dayno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"886_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654\u201362.","journal-title":"N Engl J Med"},{"key":"886_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy: clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15:519\u201339.","journal-title":"Nat Rev Neurol"},{"key":"886_CR3","volume-title":"The International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. The International Classification of Sleep Disorders. Darien: American Academy of Sleep Medicine; 2014."},{"key":"886_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","volume":"20","author":"CE Mahoney","year":"2019","unstructured":"Mahoney CE, Cogswell A, Koralnik IJ, et al. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20:83\u201393.","journal-title":"Nat Rev Neurosci"},{"key":"886_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1474-4422(14)70218-2","volume":"14","author":"RS Liblau","year":"2015","unstructured":"Liblau RS, Vassalli A, Seifinejad A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14:318\u201328.","journal-title":"Lancet Neurol"},{"key":"886_CR6","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.sleep.2019.11.290","volume":"64","author":"R Evans","year":"2019","unstructured":"Evans R, Tanaka S, Tanaka S, et al. A phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes. Sleep Med. 2019;64:S105\u20136.","journal-title":"Sleep Med"},{"key":"886_CR7","unstructured":"ClinicalTrials.gov. A study of TAK-994 in adults with type 1 and type 2 narcolepsy, study NCT04096560. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04096560. Accessed 12 Nov 2021."},{"key":"886_CR8","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/14656566.2021.1915987","volume":"22","author":"G Pellitteri","year":"2021","unstructured":"Pellitteri G, de Biase S, Valente M, et al. How treatable is narcolepsy with current pharmacotherapy and what does the future hold? Expert Opin Pharmacother. 2021;22:1517\u201320.","journal-title":"Expert Opin Pharmacother"},{"key":"886_CR9","doi-asserted-by":"publisher","first-page":"175628641987562","DOI":"10.1177\/1756286419875622","volume":"12","author":"L Barateau","year":"2019","unstructured":"Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:1756286419875622.","journal-title":"Ther Adv Neurol Disord"},{"key":"886_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","volume":"34","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34:9\u201327.","journal-title":"CNS Drugs"},{"key":"886_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.sleep.2019.09.001","volume":"68","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020;68:97\u2013109.","journal-title":"Sleep Med"},{"key":"886_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsy183","volume":"42","author":"TE Scammell","year":"2019","unstructured":"Scammell TE, Jackson AC, Franks NP, et al. Histamine: neural circuits and new medications. Sleep. 2019;42:1\u20138.","journal-title":"Sleep"},{"key":"886_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrn3526","volume":"14","author":"P Panula","year":"2013","unstructured":"Panula P, Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat Rev Neurosci. 2013;14:472\u201387.","journal-title":"Nat Rev Neurosci"},{"key":"886_CR14","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.1523\/JNEUROSCI.22-17-07695.2002","volume":"22","author":"R Parmentier","year":"2002","unstructured":"Parmentier R, Ohtsu H, Djebbara-Hannas Z, et al. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep\u2013wake control. J Neurosci. 2002;22:7695\u2013711.","journal-title":"J Neurosci"},{"key":"886_CR15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","volume":"88","author":"HL Haas","year":"2008","unstructured":"Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183\u2013241.","journal-title":"Physiol Rev"},{"key":"886_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","volume":"163","author":"JC Schwartz","year":"2011","unstructured":"Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163:713\u201321.","journal-title":"Br J Pharmacol"},{"key":"886_CR17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1212\/WNL.0b013e3181f884b1","volume":"75","author":"EE Benarroch","year":"2010","unstructured":"Benarroch EE. Histamine in the CNS: multiple functions and potential neurologic implications. Neurology. 2010;75:1472\u20139.","journal-title":"Neurology"},{"key":"886_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/327117a0","volume":"327","author":"JM Arrang","year":"1987","unstructured":"Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and selective ligands for histamine H3-receptors. Nature. 1987;327:117\u201323.","journal-title":"Nature"},{"key":"886_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1124\/mol.116.104752","volume":"90","author":"G Nieto-Alamilla","year":"2016","unstructured":"Nieto-Alamilla G, M\u00e1rquez-G\u00f3mez R, Garc\u00eda-G\u00e1lvez AM, et al. The histamine H3 receptor: structure, pharmacology, and function. Mol Pharmacol. 2016;90:649\u201373.","journal-title":"Mol Pharmacol"},{"key":"886_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14656566.2020.1817387","volume":"22","author":"S de Biase","year":"2021","unstructured":"de Biase S, Pellitteri G, Gigli GL, et al. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother. 2021;22:155\u201362.","journal-title":"Expert Opin Pharmacother"},{"key":"886_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40263-020-00703-x","volume":"34","author":"YN Lamb","year":"2020","unstructured":"Lamb YN. Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs. 2020;34:207\u201318.","journal-title":"CNS Drugs"},{"key":"886_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1124\/jpet.110.170134","volume":"336","author":"JS Lin","year":"2011","unstructured":"Lin JS, Sergeeva OA, Haas HL. Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther. 2011;336:17\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"886_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1124\/jpet.106.111039","volume":"320","author":"X Ligneau","year":"2007","unstructured":"Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{ 3-[3-(4-chlorophenyl) propoxy] propyl} piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320:365\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"886_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"JS Lin","year":"2008","unstructured":"Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients. Neurobiol Dis. 2008;30:74\u201383.","journal-title":"Neurobiol Dis"},{"key":"886_CR25","unstructured":"Wakix\u00ae (pitolisant) tablets, for oral use. Package insert. Plymouth Meeting (PA): Harmony Biosciences, LLC; 2020."},{"key":"886_CR26","unstructured":"Wakix\u00ae. Summary of product characteristics [SPC]. https:\/\/www.ema.europa.eu\/documents\/product-information\/wakix-epar-product-information_en.pdf. Accessed 12 Nov 2021."},{"key":"886_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"2","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;2:1068\u201375.","journal-title":"Lancet Neurol"},{"key":"886_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","volume":"16","author":"Z Szakacs","year":"2017","unstructured":"Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:200\u20137.","journal-title":"Lancet Neurol"},{"key":"886_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsz174","volume":"42","author":"Y Dauvilliers","year":"2019","unstructured":"Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III study. Sleep. 2019;42:1\u201311.","journal-title":"Sleep"},{"key":"886_CR30","first-page":"26","volume":"11","author":"L Citrome","year":"2014","unstructured":"Citrome L. Quantifying clinical relevance. Innov Clin Neurosci. 2014;11:26\u201330.","journal-title":"Innov Clin Neurosci"},{"key":"886_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67:407\u201311.","journal-title":"Int J Clin Pract"},{"key":"886_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540\u20135.","journal-title":"Sleep"},{"key":"886_CR33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/sleep\/20.10.844","volume":"20","author":"M Johns","year":"1997","unstructured":"Johns M, Hocking B. Excessive daytime sleepiness: daytime sleepiness and sleep habits of Australian workers. Sleep. 1997;20:844\u20139.","journal-title":"Sleep"},{"key":"886_CR34","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Mahwah: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"886_CR35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863.","journal-title":"Front Psychol"},{"key":"886_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.sleep.2016.07.010","volume":"24","author":"J Black","year":"2016","unstructured":"Black J, Swick T, Bogan R, et al. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57\u201362.","journal-title":"Sleep Med"},{"key":"886_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1017\/S031716710000439X","volume":"32","author":"M Bussi\u00e8re","year":"2005","unstructured":"Bussi\u00e8re M, Wiebe S. Progress in clinical neurosciences: measuring the benefit of therapies for neurological disorders. Can J Neurol Sci. 2005;32:419\u201324.","journal-title":"Can J Neurol Sci"},{"key":"886_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.5664\/jcsm.9006","volume":"17","author":"R Rosenberg","year":"2021","unstructured":"Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021;17:711\u20137.","journal-title":"J Clin Sleep Med"},{"key":"886_CR39","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1185\/030079906X100050","volume":"22","author":"JR Harsh","year":"2006","unstructured":"Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22:761\u201374.","journal-title":"Curr Med Res Opin"},{"key":"886_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12628","volume":"27","author":"AD Steffen","year":"2018","unstructured":"Steffen AD, Lai C, Weaver TE. Criteria for gauging response to sodium oxybate for narcolepsy. J Sleep Res. 2018;27: e12628.","journal-title":"J Sleep Res"},{"key":"886_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.sleep.2017.07.006","volume":"38","author":"L Scrima","year":"2017","unstructured":"Scrima L, Emsellem HA, Becker PM, et al. Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110. Sleep Med. 2017;38:108\u201312.","journal-title":"Sleep Med"},{"key":"886_CR42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1017\/S031716710000442X","volume":"32","author":"M Bussi\u00e8re","year":"2005","unstructured":"Bussi\u00e8re M, Wiebe S. The numbers needed to treat for neurological disorders. Can J Neurol Sci. 2005;32:440\u20139.","journal-title":"Can J Neurol Sci"},{"key":"886_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bcp.12083","volume":"76","author":"PN Bodalia","year":"2013","unstructured":"Bodalia PN, Grosso AM, Sofat R, et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. Br J Clin Pharmacol. 2013;76:649\u201367.","journal-title":"Br J Clin Pharmacol"},{"key":"886_CR44","volume":"7","author":"F Brigo","year":"2020","unstructured":"Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2020;7: CD001416.","journal-title":"Cochrane Database Syst Rev"},{"key":"886_CR45","first-page":"45","volume":"9","author":"JU Adelman","year":"2003","unstructured":"Adelman JU. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manage Care Pharm. 2003;9:45\u201352.","journal-title":"J Manage Care Pharm."},{"issue":"12","key":"886_CR46","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40263-021-00866-1","volume":"35","author":"NF Watson","year":"2021","unstructured":"Watson NF, Davis CW, Zarycranski D, et al. Time to onset of response to pitolisant for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy: an analysis of randomized placebo-controlled trials. CNS Drugs. 2021;35(12):1303\u201315.","journal-title":"CNS Drugs"},{"key":"886_CR47","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.sleep.2021.02.037","volume":"81","author":"CW Davis","year":"2021","unstructured":"Davis CW, Kallweit U, Schwartz J-C, et al. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies. Sleep Med. 2021;81:210\u20137.","journal-title":"Sleep Med"},{"key":"886_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsz252","volume":"43","author":"B Setnik","year":"2020","unstructured":"Setnik B, McDonnell M, Mills C, et al. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist\/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2020;43:1\u201312.","journal-title":"Sleep"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00886-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00886-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00886-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T21:07:47Z","timestamp":1676149667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00886-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00886-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"28 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These studies (NCT01067222, NCT01800045) were funded by Bioprojet Pharma, Paris, France. Funding for this analysis was provided by Harmony Biosciences, LLC, Plymouth Meeting, PA, USA. Harmony Biosciences, LLC also funded open access publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"GJM reports serving on advisory boards and on the speakers\u2019 bureau for Harmony Biosciences and Jazz Pharmaceuticals. CWD, DZ, MD, and JMD are employees of Harmony Biosciences. JCS is a co-founder of Bioprojet Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The datasets generated and\/or analyzed for the current study are not publicly available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"GJM: data analysis and interpretation, and review and editing of the article; CWD: conceptualization, data analysis and interpretation, and review and editing of the article; DZ: conceptualization, data analysis and interpretation, and review and editing of the article; MD: data analysis and interpretation, and review and editing of the article; JCS: data analysis and interpretation, and review and editing of the article; and JMD: data analysis and interpretation, and review and editing of the article. All authors provided input into the drafting of the manuscript, reviewed and approved the final version, and agree to be accountable for the work presented in the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Both studies (NCT01067222, NCT01800045) were conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation and the ethical principles of the Declaration of Helsinki. Each study protocol was approved by an institutional review board or independent ethics committee at each study site.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before study enrollment.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}